Viewing nowCombinationPazomet 15/850 mg
Pioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Dongku Bio Pharmaceutical Co., Ltd.

MFDS item code 201901835 · Approved 2019.03.27 · Insurance code 657307370
Improvement of blood glucose control in patients with type 2 diabetes mellitus
This medication is used to improve blood glucose control in patients with type 2 diabetes who are undergoing dietary and exercise therapy.
In the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine once daily, assess the adequacy of the treatment response, and gradually adjust the dose. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their existing doses of pioglitazone and metformin. No studies have examined the safety and efficacy of switching from another oral blood glucose-lowering agent to this medicine. Any change in a type 2 diabetes treatment regimen may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on a careful assessment of renal function. In general, the dose of this medicine should not be increased to the maximum dose in elderly, debilitated, or malnourished patients. After administration of this medicine to a patient, or when increasing the dose, the patient must be carefully monitored for adverse reactions associated with fluid retention. This medicine should generally be taken in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is required to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to assess changes in HbA1C.
This medication is primarily composed of two ingredients, and precautions may differ based on each component. The first ingredient is Metformin, which can rarely cause serious lactic acidosis. Lactic acidosis is a dangerous condition caused by excessive accumulation of lactic acid in the body and may occur more frequently in patients with impaired kidney function or issues with the heart or lungs. If symptoms such as shortness of breath, muscle pain, fatigue, or abdominal pain occur, you should immediately inform your physician. Additionally, this medication should not be administered to patients with reduced kidney function, and it is advisable to avoid its use in cases of impaired liver function. Excessive alcohol consumption can affect the metabolism of lactic acid by this medication, increasing the risk of side effects, so alcohol should be avoided while taking it. The second ingredient is Pioglitazone, which may worsen heart failure and should not be used in patients with severely impaired heart function. If symptoms of heart failure, such as weight gain, edema, or dyspnea occur during treatment, you must immediately notify healthcare personnel. Moreover, this medication should be administered cautiously in patients with a history of bladder cancer, and symptoms such as urinary obstruction or hematuria should be reported to your doctor immediately. Female patients may need to be aware of the increased risk of fractures with long-term use. This medication should not be given to women who are pregnant or breastfeeding, and safety in children has not been established. Elderly patients may require dose adjustments and regular kidney function tests due to the possibility of impaired renal function. Furthermore, this medication may interact with several other drugs, so you must inform healthcare personnel of any other medications you are taking. Before surgery or tests involving iodine contrast agents, this medication should be temporarily discontinued and restarted only after confirming normal kidney function. Finally, during the use of this medication, regular monitoring of blood glucose, kidney function, liver function, and hematological values is necessary to check for abnormalities, and you should consult healthcare personnel immediately if symptoms occur.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or humidity, so it should be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the medication's effectiveness and safety for a longer period.
White to grayish-white rectangular film-coated tablets
30 tablets (10 tablets/Alu-Alu×3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationPioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Dongku Bio Pharmaceutical Co., Ltd.
Pioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationMetformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Dalim Biotech Co., Ltd.
CombinationPioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.
Metformin Hydrochloride · Pioglitazone Hydrochloride
Prescription medication · Combination
Nexpam Korea Co., Ltd.
CombinationPioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Ilhwa Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.